

# Treatment of renal cell carcinoma: Current status and f

Ca-A Cancer Journal for Clinicians

67, 507-524

DOI: [10.3322/caac.21411](https://doi.org/10.3322/caac.21411)

Citation Report

#	ARTICLE	IF	CITATIONS
1	miR-566 functions as an oncogene and a potential biomarker for prognosis in renal cell carcinoma. <i>Biomedicine and Pharmacotherapy</i> , 2018, 102, 718-727.	2.5	16
2	Current and Emerging Therapeutic Targets for Metastatic Renal Cell Carcinoma. <i>Current Oncology Reports</i> , 2018, 20, 41.	1.8	16
3	Genetic polymorphisms associated with adverse reactions of molecular-targeted therapies in renal cell carcinoma. <i>Medical Oncology</i> , 2018, 35, 16.	1.2	8
4	Predictors of Cancer-specific Survival After Disease Recurrence in Patients With Renal Cell Carcinoma: The Effect of Time to Recurrence. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e903-e908.	0.9	16
5	Vascular toxicities with VEGF inhibitor therapies—focus on hypertension and arterial thrombotic events. <i>Journal of the American Society of Hypertension</i> , 2018, 12, 409-425.	2.3	141
6	Immunotherapy in Advanced Renal Cancer — Is Cure Possible?. <i>New England Journal of Medicine</i> , 2018, 378, 1344-1345.	13.9	10
7	T-cell large granular lymphocytic leukemia associated with renal cell carcinoma. <i>Medicine (United States)</i> , 2018, 97, 1000000.	0.4	2
8	VEG174 protein and its functional domain peptides exert antitumour effects on renal cell carcinoma. <i>International Journal of Oncology</i> , 2018, 54, 390-398.	1.4	0
9	Role of APLP2 in the prognosis and clinicopathology of renal cell carcinoma. <i>Oncology Letters</i> , 2019, 17, 508-513.	0.8	7
10	Cardiovascular oncology: exploring the effects of targeted cancer therapies on atherosclerosis. <i>Current Opinion in Lipidology</i> , 2018, 29, 381-388.	1.2	8
11	Loss of SETD2 Induces a Metabolic Switch in Renal Cell Carcinoma Cell Lines toward Enhanced Oxidative Phosphorylation. <i>Journal of Proteome Research</i> , 2019, 18, 331-340.	1.8	27
12	Intramedullary Spinal Cord Metastasis from Renal Cell Carcinoma: A Systematic Review of the Literature. <i>BioMed Research International</i> , 2018, 2018, 1-7.	0.9	9
13	Identification of biomarkers of chromophobe renal cell carcinoma by weighted gene co-expression network analysis. <i>Cancer Cell International</i> , 2018, 18, 206.	1.8	22
14	Integrated analysis of long noncoding RNA associated competing endogenous RNA as prognostic biomarkers in clear cell renal carcinoma. <i>Cancer Science</i> , 2018, 109, 3336-3349.	1.7	33
15	The Costly War Against Cancer Treatment: The Example of Metastatic Renal Cell Carcinoma in Portugal. <i>Acta Medica Portuguesa</i> , 2018, 31, 373.	0.2	1
16	Clinicopathologic Significance of VHL Gene Alteration in Clear-Cell Renal Cell Carcinoma: An Updated Meta-Analysis and Review. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2529.	1.8	27
17	The expression and function of RASAL2 in renal cell carcinoma angiogenesis. <i>Cell Death and Disease</i> , 2018, 9, 881.	2.7	22
18	Novel insights into biomarkers associated with renal cell carcinoma. <i>Oncology Letters</i> , 2018, 16, 83-90.	0.8	16

#	ARTICLE	IF	CITATIONS
19	Cytoreductive nephrectomy: questions remain after CARMENA. <i>Nature Reviews Urology</i> , 2018, 15, 530-532.	1.9	5
20	Long non-coding RNA HOTTIP is upregulated in renal cell carcinoma and regulates cell growth and apoptosis by epigenetically silencing of LATS2. <i>Biomedicine and Pharmacotherapy</i> , 2018, 105, 1133-1140.	2.5	24
21	Living with Advanced Kidney Cancer and Treatment with Cabozantinib: Through the Eyes of the Patient and the Physician. <i>Oncology and Therapy</i> , 2018, 6, 1-7.	1.0	2
22	MiR-532-5p suppresses renal cancer cell proliferation by disrupting the ETS1-mediated positive feedback loop with the KRAS-NAP1L1/P-ERK axis. <i>British Journal of Cancer</i> , 2018, 119, 591-604.	2.9	63
23	Unexpected Gallbladder Metastasis of Clear Cell Renal Carcinoma. <i>BMC Clinical Pathology</i> , 2019, 12, 2632010X1986111.	0.7	6
24	Laminâ€B1 is a senescenceâ€associated biomarker in clearâ€cell renal cell carcinoma. <i>Oncology Letters</i> , 2019, 18, 2654-2660.	0.8	24
25	&lt;p&gt;SNHG15: a promising cancer-related long noncoding RNA&lt;p&gt;. <i>Cancer Management and Research</i> , 2019, Volume 11, 5961-5969.	0.9	48
26	Health Benefits of Resveratrol in Kidney Disease: Evidence from In Vitro and In Vivo Studies. <i>Nutrients</i> , 2019, 11, 1624.	1.7	60
27	MAGI1 mediates tumor metastasis through c-Myb/miR-520h/MAGI1 signaling pathway in renal cell carcinoma. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2019, 24, 837-848.	2.2	8
28	Tropomyosin-1 Functions as a Tumor Suppressor with Respect to Cell Proliferation, Angiogenesis and Metastasis in Renal Cell Carcinoma. <i>Journal of Cancer</i> , 2019, 10, 2220-2228.	1.2	22
29	AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. <i>Molecular Cancer</i> , 2019, 18, 153.	7.9	279
30	EIF3D promotes sunitinib resistance of renal cell carcinoma by interacting with GRP78 and inhibiting its degradation. <i>EBioMedicine</i> , 2019, 49, 189-201.	2.7	29
31	Extracellular vesicles in urologic malignanciesâ€Implementations for future cancer care. <i>Cell Proliferation</i> , 2019, 52, e12659.	2.4	20
32	<i>SETD2</i> loss sensitizes cells to PI3KÎ² and AKT inhibition. <i>Oncotarget</i> , 2019, 10, 647-659.	0.8	7
33	Cell death-related molecules and biomarkers for renal cell carcinoma targeted therapy. <i>Cancer Cell International</i> , 2019, 19, 221.	1.8	25
34	Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results. <i>Journal of Translational Medicine</i> , 2019, 17, 296.	1.8	13
35	Down-Regulation of Circular RNA_000926 Attenuates Renal Cell Carcinoma Progression through miRNA-411â€Dependent CDH2 Inhibition. <i>American Journal of Pathology</i> , 2019, 189, 2469-2486.	1.9	33
36	Comparative STAT3-Regulated Gene Expression Profile in Renal Cell Carcinoma Subtypes. <i>Frontiers in Oncology</i> , 2019, 9, 72.	1.3	27

#	ARTICLE	IF	CITATIONS
37	CXCL13/CXCR5 Axis Predicts Poor Prognosis and Promotes Progression Through PI3K/AKT/mTOR Pathway in Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2018, 8, 682.	1.3	70
38	DNA methylation of CRB3 is a prognostic biomarker in clear cell renal cell carcinoma. <i>Molecular Biology Reports</i> , 2019, 46, 4377-4383.	1.0	6
39	Clinical Efficacy and Complication Rate of Sunitinib 2/1 Versus 4/2 Schedule for the Treatment of Metastatic Renal Cell Cancer: A Systematic Review and Meta-Analysis. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 319-331.	0.9	6
40	TUSC3 as a potential biomarker for prognosis in clear cell renal cell carcinoma. <i>Oncology Letters</i> , 2019, 17, 5073-5079.	0.8	3
41	Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2019, 114, 67-75.	1.3	88
42	The Metabolic Basis of Kidney Cancer. <i>Cancer Discovery</i> , 2019, 9, 1006-1021.	7.7	163
43	An essential role for GLUT5-mediated fructose utilization in exacerbating the malignancy of clear cell renal cell carcinoma. <i>Cell Biology and Toxicology</i> , 2019, 35, 471-483.	2.4	18
44	Folic Acid Reduces Mucositis in Metastatic Renal Cell Carcinoma Patients: A Retrospective Study. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 254-259.	0.9	4
45	Extracellular Vesicles and Carried miRNAs in the Progression of Renal Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1832.	1.8	38
46	miR-4521-FAM129A axial regulation on ccRCC progression through TIMP-1/MMP2/MMP9 and MDM2/p53/Bcl2/Bax pathways. <i>Cell Death Discovery</i> , 2019, 5, 89.	2.0	34
47	Immune infiltration in renal cell carcinoma. <i>Cancer Science</i> , 2019, 110, 1564-1572.	1.7	251
48	CD103-positive CSC exosome promotes EMT of clear cell renal cell carcinoma: role of remote MiR-19b-3p. <i>Molecular Cancer</i> , 2019, 18, 86.	7.9	149
49	Histologic Diagnosis of Renal Mass Biopsy. <i>Archives of Pathology and Laboratory Medicine</i> , 2019, 143, 705-710.	1.2	15
50	Predictive models composed by radiomic features extracted from multi-detector computed tomography images for predicting low- and high- grade clear cell renal cell carcinoma. <i>Medicine (United States)</i> , 2019, 98, e13957.	0.4	7
51	Systemic therapy in the management of localized and locally advanced renal cell carcinoma: Current state and future perspectives. <i>International Journal of Urology</i> , 2019, 26, 532-542.	0.5	31
52	Addressable Peptide Self-Assembly on the Cancer Cell Membrane for Sensitizing Chemotherapy of Renal Cell Carcinoma. <i>Advanced Materials</i> , 2019, 31, e1807175.	11.1	69
53	PD-1 blockade enhances the anti-tumor immune response induced by cryoablation in a murine model of renal cell carcinoma. <i>Cryobiology</i> , 2019, 87, 86-90.	0.3	14
54	Best treatment options for advanced renal cell carcinoma (RCC) patients: a Delphi consensus study. <i>Medical Oncology</i> , 2019, 36, 29.	1.2	0

#	ARTICLE	IF	CITATIONS
55	Blocking CD47 efficiently potentiated therapeutic effects of anti-angiogenic therapy in non-small cell lung cancer. , 2019, 7, 346.		65
56	Gankyrin is a novel biomarker for disease progression and prognosis of patients with renal cell carcinoma. EBioMedicine, 2019, 39, 255-264.	2.7	14
57	Clear cell renal cell carcinoma with wild-type <i>CD47</i> gene: a non-existent or new tumour entity?. Histopathology, 2019, 74, 60-67.	1.6	27
58	The molecular characterization and therapeutic strategies of papillary renal cell carcinoma. Expert Review of Anticancer Therapy, 2019, 19, 169-175.	1.1	10
59	Economic Burden of Renal Cell Carcinoma—Part I: An Updated Review. Pharmacoeconomics, 2019, 37, 301-331.	1.7	25
60	CEP55 promotes epithelial-mesenchymal transition in renal cell carcinoma through PI3K/AKT/mTOR pathway. Clinical and Translational Oncology, 2019, 21, 939-949.	1.2	47
61	Therapeutics for advanced hepatocellular carcinoma: Recent advances, current dilemma, and future directions. Journal of Cellular Physiology, 2019, 234, 12122-12132.	2.0	47
62	Dynamic changes of different phenotypic and genetic circulating tumor cells as a biomarker for evaluating the prognosis of RCC. Cancer Biology and Therapy, 2019, 20, 505-512.	1.5	24
63	Radical shifts in the first-line management of metastatic renal cell carcinoma. Nature Reviews Clinical Oncology, 2019, 16, 71-72.	12.5	4
64	Preoperative apolipoprotein B/A1 ratio is an independent prognostic factor in metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 184.e9-184.e17.	0.8	13
65	Grading of Clear Cell Renal Cell Carcinomas by Using Machine Learning Based on Artificial Neural Networks and Radiomic Signatures Extracted From Multidetector Computed Tomography Images. Academic Radiology, 2020, 27, 157-168.	1.3	19
66	CircRNA cRAPGEF5 inhibits the growth and metastasis of renal cell carcinoma via the miR-27a-3p/TXNIP pathway. Cancer Letters, 2020, 469, 68-77.	3.2	133
67	Rare patients in routine care: Treatment and outcome in advanced papillary renal cell carcinoma in the prospective German clinical RCC Registry. International Journal of Cancer, 2020, 146, 1307-1315.	2.3	6
68	miR-26 suppresses renal cell cancer via down-regulating coronin-3. Molecular and Cellular Biochemistry, 2020, 463, 137-146.	1.4	12
69	Evaluation of the prognostic role of co-morbidities on disease outcome in renal cell carcinoma patients. World Journal of Urology, 2020, 38, 1525-1533.	1.2	5
70	Treatment Outcome of metastatic lesions from renal cell carcinoma under Going Extra-cranial stereotactic body radiotherapy: The together retrospective study. Cancer Treatment and Research Communications, 2020, 22, 100161.	0.7	18
71	MicroRNA-96 is a potential tumor repressor by inhibiting NPTX2 in renal cell carcinoma. Journal of Cellular Biochemistry, 2020, 121, 1504-1513.	1.2	8
72	SH3BGRL2 inhibits growth and metastasis in clear cell renal cell carcinoma via activating hippo/TEAD1-Twist1 pathway. EBioMedicine, 2020, 51, 102596.	2.7	49

#	ARTICLE	IF	CITATIONS
73	MSRB3 promotes the progression of clear cell renal cell carcinoma via regulating endoplasmic reticulum stress. <i>Pathology Research and Practice</i> , 2020, 216, 152780.	1.0	7
74	Knockdown of MAPK14 inhibits the proliferation and migration of clear cell renal cell carcinoma by downregulating the expression of CDC25B. <i>Cancer Medicine</i> , 2020, 9, 1183-1195.	1.3	20
75	Cancer patients with potential eligibility for vascular endothelial growth factor antagonists use have an increased risk for cardiovascular diseases comorbidities. <i>Journal of Hypertension</i> , 2020, 38, 426-433.	0.3	15
76	Blockade of Adenosine A2b Receptor Reduces Tumor Growth and Migration in Renal Cell Carcinoma. <i>Journal of Cancer</i> , 2020, 11, 421-431.	1.2	18
77	Prognostic value of infiltrating immune cells in clear cell renal cell carcinoma (ccRCC). <i>Journal of Cellular Biochemistry</i> , 2020, 121, 2571-2581.	1.2	21
78	Imaging of Renal Cancer. <i>Seminars in Ultrasound, CT and MRI</i> , 2020, 41, 152-169.	0.7	11
79	Sertraline/ICG-loaded liposome for dual-modality imaging and effective chemo-photothermal combination therapy against metastatic clear cell renal cell carcinoma. <i>Chemical Biology and Drug Design</i> , 2020, 95, 320-331.	1.5	8
80	Identification of Immune-Related Cells and Genes in Tumor Microenvironment of Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 1770.	1.3	7
81	RCC Immune Microenvironment Subsequent to Targeted Therapy: A Friend or a Foe?. <i>Frontiers in Oncology</i> , 2020, 10, 573690.	1.3	6
82	Circular RNAs in renal cell carcinoma: implications for tumorigenesis, diagnosis, and therapy. <i>Molecular Cancer</i> , 2020, 19, 149.	7.9	65
83	Tumor Cell-Derived TGF $\beta$ 1 Attenuates Antitumor Immune Activity of T Cells via Regulation of PD-1 mRNA. <i>Cancer Immunology Research</i> , 2020, 8, 1470-1484.	1.6	28
84	Chromodomain Helicase DNA-Binding Protein 5 Inhibits Renal Cell Carcinoma Tumorigenesis by Activation of the p53 and RB Pathways. <i>BioMed Research International</i> , 2020, 2020, 1-12.	0.9	2
85	Renal cell carcinoma with nephrotic syndrome: a case report and literature review. <i>Translational Andrology and Urology</i> , 2020, 9, 1459-1465.	0.6	7
86	LAGE3 correlates with tumorigenic immune infiltrates in the clear cell renal cell carcinoma microenvironment. <i>International Immunopharmacology</i> , 2020, 87, 106793.	1.7	15
87	Development and validation of an integrative methylation signature and nomogram for predicting survival in clear cell renal cell carcinoma. <i>Translational Andrology and Urology</i> , 2020, 9, 1082-1098.	0.6	8
88	A-kinase interacting protein 1 high expression correlates with advanced tumor stage and poor overall survival in surgical patients with clear cell renal cell carcinoma. <i>Medicine (United States)</i> , 2020, 99, e20742.	0.4	5
89	Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort. <i>Frontiers in Oncology</i> , 2020, 10, 581189.	1.3	11
90	Upregulated circPDK1 Promotes RCC Cell Migration and Invasion by Regulating the miR-377-3P-NOTCH1 Axis in Renal Cell Carcinoma. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 11237-11252.	1.0	21

#	ARTICLE	IF	CITATIONS
91	IGFLR1 as a Novel Prognostic Biomarker in Clear Cell Renal Cell Cancer Correlating With Immune Infiltrates. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 565173.	1.6	8
92	FCGR1A Serves as a Novel Biomarker and Correlates With Immune Infiltration in Four Cancer Types. <i>Frontiers in Molecular Biosciences</i> , 2020, 7, 581615.	1.6	14
93	The miRâ€140â€5p/KLF9/KCNQ1 axis promotes the progression of renal cell carcinoma. <i>FASEB Journal</i> , 2020, 34, 10623-10639.	0.2	20
94	Identification of a three-long noncoding RNA prognostic model involved competitive endogenous RNA in kidney renal clear cell carcinoma. <i>Cancer Cell International</i> , 2020, 20, 319.	1.8	25
95	The role of income disparities on survival in metastatic clear cell renal cell carcinoma in the targeted therapy era. <i>European Journal of Health Economics</i> , 2020, 21, 1223-1233.	1.4	4
96	Integrative bioinformatics analysis of a prognostic index and immunotherapeutic targets in renal cell carcinoma. <i>International Immunopharmacology</i> , 2020, 87, 106832.	1.7	7
97	Factors Associated With Receipt of Partial Nephrectomy or Minimally Invasive Surgery for Patients With Clinical T1a and T1b Renal Masses: Implications for Regionalization of Care. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e643-e650.	0.9	5
98	Identification and Comprehensive Validation of a DNA Methylation-Driven Gene-Based Prognostic Model for Clear Cell Renal Cell Carcinoma. <i>DNA and Cell Biology</i> , 2020, 39, 1799-1812.	0.9	11
99	Combination of tumor suppressor miR-20b-5p, miR-30a-5p, and miR-196a-5p as a serum diagnostic panel for renal cell carcinoma. <i>Pathology Research and Practice</i> , 2020, 216, 153152.	1.0	12
100	Identification of KIF18B as a Hub Candidate Gene in the Metastasis of Clear Cell Renal Cell Carcinoma by Weighted Gene Co-expression Network Analysis. <i>Frontiers in Genetics</i> , 2020, 11, 905.	1.1	10
101	Cell Polarity Protein Pals1-Associated Tight Junction Expression Is a Favorable Prognostic Marker in Clear Cell Renal Cell Carcinoma. <i>Frontiers in Genetics</i> , 2020, 11, 931.	1.1	6
102	Long Non-coding RNA IRAIN Inhibits VEGFA Expression via Enhancing Its DNA Methylation Leading to Tumor Suppression in Renal Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 1082.	1.3	9
103	TRIM33 Overexpression Inhibits the Progression of Clear Cell Renal Cell Carcinoma In Vivo and In Vitro. <i>BioMed Research International</i> , 2020, 2020, 1-18.	0.9	8
104	ApoC1 promotes the metastasis of clear cell renal cell carcinoma via activation of STAT3. <i>Oncogene</i> , 2020, 39, 6203-6217.	2.6	45
105	Acyl-CoA Thioesterase 8 and 11 as Novel Biomarkers for Clear Cell Renal Cell Carcinoma. <i>Frontiers in Genetics</i> , 2020, 11, 594969.	1.1	17
106	Poly(U) binding splicing factor 60 promotes renal cell carcinoma growth by transcriptionally upregulating telomerase reverse transcriptase. <i>International Journal of Biological Sciences</i> , 2020, 16, 3002-3017.	2.6	6
107	Establishment of predictive model for patients with kidney cancer bone metastasis: a study based on SEER database. <i>Translational Andrology and Urology</i> , 2020, 9, 523-543.	0.6	9
108	Construction and Validation of an Autophagy-Related Prognostic Risk Signature for Survival Predicting in Clear Cell Renal Cell Carcinoma Patients. <i>Frontiers in Oncology</i> , 2020, 10, 707.	1.3	12

#	ARTICLE	IF	CITATIONS
109	MUC15 inhibits cancer metastasis via PI3K/AKT signaling in renal cell carcinoma. <i>Cell Death and Disease</i> , 2020, 11, 336.	2.7	24
110	Therapeutic Targeting of Autophagy for Renal Cell Carcinoma Therapy. <i>Cancers</i> , 2020, 12, 1185.	1.7	31
111	Identification of biomarkers of clear cell renal cell carcinoma by bioinformatics analysis. <i>Medicine (United States)</i> , 2020, 99, e20470.	0.4	4
112	miR-429-CRKL axis regulates clear cell renal cell carcinoma malignant progression through SOS1/MEK/ERK/MMP2/MMP9 pathway. <i>Biomedicine and Pharmacotherapy</i> , 2020, 127, 110215.	2.5	17
113	The pattern and prognostic relevance of immune activity scores and tumor-infiltrating immune cells in metastatic clear cell renal cell carcinoma: Evidence from multiple datasets. <i>International Immunopharmacology</i> , 2020, 85, 106651.	1.7	4
114	A 17-Gene Signature Predicted Prognosis in Renal Cell Carcinoma. <i>Disease Markers</i> , 2020, 2020, 1-9.	0.6	6
115	Profiles of immune cell infiltration and their clinical significance in head and neck squamous cell carcinoma. <i>International Immunopharmacology</i> , 2020, 82, 106364.	1.7	18
116	Identification of the key genes and pathways involved in the tumorigenesis and prognosis of kidney renal clear cell carcinoma. <i>Scientific Reports</i> , 2020, 10, 4271.	1.6	44
117	Mining therapeutic and prognostic significance of STATs in renal cell carcinoma with bioinformatics analysis. <i>Genomics</i> , 2020, 112, 4100-4114.	1.3	20
118	Identification of gene signature for treatment response to guide precision oncology in clear-cell renal cell carcinoma. <i>Scientific Reports</i> , 2020, 10, 2026.	1.6	16
119	Modeling clear cell renal cell carcinoma and therapeutic implications. <i>Oncogene</i> , 2020, 39, 3413-3426.	2.6	86
121	Potential New Therapeutic Approaches for Renal Cell Carcinoma. <i>Seminars in Nephrology</i> , 2020, 40, 86-97.	0.6	30
122	CBX4 transcriptionally suppresses KLF6 via interaction with HDAC1 to exert oncogenic activities in clear cell renal cell carcinoma. <i>EBioMedicine</i> , 2020, 53, 102692.	2.7	30
123	Expression signature of six lncRNA serves as novel non-invasive biomarker for diagnosis and prognosis prediction of renal clear cell carcinoma. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 2215-2228.	1.6	32
124	Development and validation of a robust multigene signature as an aid to predict early relapse in stage I-III clear cell and papillary renal cell cancer. <i>Journal of Cancer</i> , 2020, 11, 997-1007.	1.2	9
125	PRMT7 promotes the growth of renal cell carcinoma through modulating the $\beta$ -catenin/C-MYC axis. <i>International Journal of Biochemistry and Cell Biology</i> , 2020, 120, 105686.	1.2	23
126	Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma. <i>EBioMedicine</i> , 2020, 55, 102755.	2.7	12
127	Identification of the Potential Prognostic Markers from the miRNA-lncRNA-mRNA Interactions for Metastatic Renal Cancer via Next-Generation Sequencing and Bioinformatics. <i>Diagnostics</i> , 2020, 10, 228.	1.3	10



#	ARTICLE	IF	CITATIONS
128	HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma. , 2020, 8, e000157.		60
129	Inhibition of BRD4 prevents proliferation and epithelialâ€mesenchymal transition in renal cell carcinoma via NLRP3 inflammasome-induced pyroptosis. Cell Death and Disease, 2020, 11, 239.	2.7	89
130	Integration of intratumoral RASSF10 expression and tumor-associated macrophages into the established clinical indicators better predicts the prognosis of clear cell renal cell carcinoma patients. Oncolmmunology, 2020, 9, 1736793.	2.1	6
131	<i>C1QTNF6</i> as a Novel Diagnostic and Prognostic Biomarker for Clear Cell Renal Cell Carcinoma. DNA and Cell Biology, 2020, 39, 1000-1011.	0.9	13
132	Pazopanib after Nivolumab-Induced Tumor Lysis Syndrome in a Patient with Metastatic Clear-Cell Renal Cell Carcinoma. Case Reports in Oncology, 2020, 13, 249-254.	0.3	3
134	Cytotoxic and antitumor peptides as novel chemotherapeutics. Natural Product Reports, 2021, 38, 7-17.	5.2	28
135	Triptolidenol, isolated from Tripterygium wilfordii, disrupted NF-Î®B/COX-2 pathway by targeting ATP-binding sites of IKKÎ² in clear cell renal cell carcinoma. FÃ-toterapÃ-Ãç, 2021, 148, 104779.	1.1	9
136	Transmembrane protein ADAM29 facilitates cell proliferation, invasion and migration in clear cell renal cell carcinoma. Journal of Chemotherapy, 2021, 33, 40-50.	0.7	2
137	Mast cell density in metastatic renal cell carcinoma: Association with prognosis and tumourâ€infiltrating lymphocytes. Scandinavian Journal of Immunology, 2021, 93, e13006.	1.3	9
138	Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors. European Urology Oncology, 2021, 4, 102-111.	2.6	26
139	Update on First-Line Combination Treatment Approaches in Metastatic Clear-Cell Renal Cell Carcinoma. Current Treatment Options in Oncology, 2021, 22, 15.	1.3	13
140	ACE2 Is a Prognostic Biomarker and Associated with Immune Infiltration in Kidney Renal Clear Cell Carcinoma: Implication for COVID-19. Journal of Oncology, 2021, 2021, 1-15.	0.6	11
141	Retroperitoneal castleman disease mimicking lymph node spread from clear renal cell carcinoma. A case report. Urology Case Reports, 2021, 34, 101503.	0.1	3
142	DDX39 as a predictor of clinical prognosis and immune checkpoint therapy efficacy in patients with clear cell renal cell carcinoma. International Journal of Biological Sciences, 2021, 17, 3158-3172.	2.6	14
143	Characteristics and prognostic value of potential dependency genes in clear cell renal cell carcinoma based on a large-scale CRISPR-Cas9 and RNAi screening database DepMap. International Journal of Medical Sciences, 2021, 18, 2063-2075.	1.1	23
144	Nodal is involved in chemoresistance of renal cell carcinoma cells via regulation of ABCB1. Journal of Cancer, 2021, 12, 2041-2049.	1.2	1
145	Integral Analysis of the RNA Binding Protein-associated Prognostic Model for Renal Cell Carcinoma. International Journal of Medical Sciences, 2021, 18, 953-963.	1.1	11
146	Identification and validation of the clinical roles of the VHL-related LncRNAs in clear cell renal cell carcinoma. Journal of Cancer, 2021, 12, 2702-2714.	1.2	22

#	ARTICLE	IF	CITATIONS
147	Prognostic Impact of MITD1 and Associates With Immune Infiltration in Kidney Renal Clear Cell Carcinoma. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110362.	0.8	6
148	Identification of unique long non-coding RNAs as putative biomarkers for chromophobe renal cell carcinoma. <i>Personalized Medicine</i> , 2021, 18, 9-19.	0.8	2
149	Trends in the kidney cancer mortality-to-incidence ratios according to health care expenditures of 56 countries. <i>Scientific Reports</i> , 2021, 11, 1479.	1.6	21
150	A genomic instability-derived risk index predicts clinical outcome and immunotherapy response for clear cell renal cell carcinoma. <i>Bioengineered</i> , 2021, 12, 1642-1662.	1.4	6
151	Silencing of the chemokine CXC receptor 4 (CXCR4) hampers cancer progression and increases cisplatin (DDP)-sensitivity in clear cell renal cell carcinoma (ccRCC). <i>Bioengineered</i> , 2021, 12, 2957-2969.	1.4	5
152	Progress Update in Pediatric Renal Tumors. <i>Current Oncology Reports</i> , 2021, 23, 33.	1.8	14
153	Effect of improved systemic therapy on patient survival in metastatic non-clear cell renal cell carcinoma. <i>International Journal of Urology</i> , 2021, 28, 605-607.	0.5	6
154	High VHL Expression Reverses Warburg Phenotype and Enhances Immunogenicity in Kidney Tumor Cells. <i>Genomics, Proteomics and Bioinformatics</i> , 2022, 20, 657-669.	3.0	5
155	CTHRC1 Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Kidney Renal Papillary Cell Carcinoma and Kidney Renal Clear Cell Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 570819.	1.3	13
156	TRIM47 promotes malignant progression of renal cell carcinoma by degrading P53 through ubiquitination. <i>Cancer Cell International</i> , 2021, 21, 129.	1.8	13
157	Differential Interactome Proposes Subtype-Specific Biomarkers and Potential Therapeutics in Renal Cell Carcinomas. <i>Journal of Personalized Medicine</i> , 2021, 11, 158.	1.1	8
158	Synergistic Effects of TW-37 and ABT-263 on Renal Cell Carcinoma Cells. <i>Cancer Management and Research</i> , 2021, Volume 13, 953-963.	0.9	7
159	Identification of a Gene Signature for Renal Cell Carcinoma-Associated Fibroblasts Mediating Cancer Progression and Affecting Prognosis. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 604627.	1.8	26
160	Prognostic nomogram for patients with lung metastatic renal cell carcinoma: a SEER-based study. <i>Annals of Palliative Medicine</i> , 2021, 10, 2791-2804.	0.5	10
162	Management of locally advanced renal cell carcinoma. <i>AME Medical Journal</i> , 0, 6, 5-5.	0.4	2
163	Multi-omics analysis of tumor angiogenesis characteristics and potential epigenetic regulation mechanisms in renal clear cell carcinoma. <i>Cell Communication and Signaling</i> , 2021, 19, 39.	2.7	31
164	PD-L1 Expression and Treatment Implications in Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review. <i>Kidney Cancer</i> , 2021, 5, 31-46.	0.2	2
165	Androgen receptor decreases renal cell carcinoma bone metastases via suppressing the osteolytic formation through altering a novel circEXOC7 regulatory axis. <i>Clinical and Translational Medicine</i> , 2021, 11, e353.	1.7	19

#	ARTICLE	IF	CITATIONS
166	Systematic Profiling of Alternative Splicing Events in Ovarian Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 622805.	1.3	2
167	Expression levels of VEGFâ€C and VEGFRâ€3 in renal cell carcinoma and their association with lymph node metastasis. <i>Experimental and Therapeutic Medicine</i> , 2021, 21, 554.	0.8	5
168	Comparative efficacy and safety of immunotherapy in the first-line treatment of metastatic renal cell carcinoma: a systematic review and network meta-analysis. <i>Annals of Palliative Medicine</i> , 2021, 10, 2805-2814.	0.5	5
169	Artificial intelligence prediction model for overall survival of clear cell renal cell carcinoma based on a 21-gene molecular prognostic score system. <i>Aging</i> , 2021, 13, 7361-7381.	1.4	7
170	The Immune-Related Gene HCST as a Novel Biomarker for the Diagnosis and Prognosis of Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 630706.	1.3	5
171	A population-based study to predict distant metastasis in patients with renal cell carcinoma. <i>Annals of Palliative Medicine</i> , 2021, 10, 4273-4288.	0.5	5
172	Randomized clinical trials and real life studies: Comparison of baseline characteristics of patients in oral target therapies for renal cell carcinoma. <i>Journal of Oncology Pharmacy Practice</i> , 2021, , 107815522110055.	0.5	5
173	Clinicopathologic Features and Survival Outcomes for Primary Renal Neuroendocrine Neoplasms. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 155-161.	0.9	8
174	HMGCR inhibition stabilizes the glycolytic enzyme PKM2 to support the growth of renal cell carcinoma. <i>PLoS Biology</i> , 2021, 19, e3001197.	2.6	19
175	The Regulating Effect of Autophagy-Related MiRNAs in Kidney, Bladder, and Prostate Cancer. <i>Journal of Oncology</i> , 2021, 2021, 1-8.	0.6	5
176	Curcumin suppresses renal carcinoma tumorigenesis by regulating circ-FNDC3B/miR-138-5p/IGF2 axis. <i>Anti-Cancer Drugs</i> , 2021, 32, 734-744.	0.7	17
177	NUPR1 is a novel potential biomarker and confers resistance to sorafenib in clear cell renal cell carcinoma by increasing stemness and targeting the PTEN/AKT/mTOR pathway. <i>Aging</i> , 2021, 13, 14015-14038.	1.4	9
178	Mechanism of gypenosides of <i>Gynostemma pentaphyllum</i> inducing apoptosis of renal cell carcinoma by PI3K/AKT/mTOR pathway. <i>Journal of Ethnopharmacology</i> , 2021, 271, 113907.	2.0	31
179	Treatment of advanced urogenital cancers with immune checkpoint inhibitors. <i>Journal of the Korean Medical Association</i> , 2021, 64, 349-357.	0.1	0
180	Identification of an independent immune-genes prognostic index for renal cell carcinoma. <i>BMC Cancer</i> , 2021, 21, 746.	1.1	2
181	Outcomes based on age in patients with metastatic renal cell carcinoma treated with first line targeted therapy or checkpoint immunotherapy: Older patients more prone to toxicity. <i>Journal of Geriatric Oncology</i> , 2021, 12, 827-833.	0.5	14
182	Oncogenic Chromatin Modifier KAT2A Activates MCT1 to Drive the Glycolytic Process and Tumor Progression in Renal Cell Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 690796.	1.8	13
183	Cytoreductive Nephrectomy Promoted Abscopal Effect of Camrelizumab Combined With Radiotherapy for Metastatic Renal Cell Carcinoma: A Case Report and Review of the Literature. <i>Frontiers in Immunology</i> , 2021, 12, 646085.	2.2	4

#	ARTICLE	IF	CITATIONS
184	KDELC1 and TRMT1 Serve as Prognosis-Related SARS-CoV-2 Proteins Binding Human mRNAs and Promising Biomarkers in Clear Cell Renal Cell Carcinoma. <i>International Journal of General Medicine</i> , 2021, Volume 14, 2475-2490.	0.8	6
185	Hypoxia-inducible factor 2 inhibitors show promise in advanced kidney cancer. <i>Nature Reviews Urology</i> , 2021, 18, 516-517.	1.9	3
186	Renal mass biopsy: A strategy to reduce associated costs and morbidity when managing localized renal masses. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 790.e9-790.e15.	0.8	4
187	Dual Targeting of Endoplasmic Reticulum by Redox-Deubiquitination Regulation for Cancer Therapy. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 5193-5209.	3.3	12
188	Small bowel obstruction caused by secondary jejunal tumor from renal cell carcinoma: A case report. <i>World Journal of Clinical Cases</i> , 2021, 9, 5339-5344.	0.3	0
189	RRM2 Regulates Sensitivity to Sunitinib and PD-1 Blockade in Renal Cancer by Stabilizing ANXA1 and Activating the AKT Pathway. <i>Advanced Science</i> , 2021, 8, e2100881.	5.6	54
190	Comprehensive Analysis of Ferroptosis Regulators With Regard to PD-L1 and Immune Infiltration in Clear Cell Renal Cell Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 676142.	1.8	29
191	IQGAP3 May Serve as a Promising Biomarker in Clear Cell Renal Cell Carcinoma. <i>International Journal of General Medicine</i> , 2021, Volume 14, 3469-3484.	0.8	2
192	CARS as a Prognosis Factor in Clear Cell Renal Cell Carcinoma and Its Association with Tumor Immunity. <i>International Journal of General Medicine</i> , 2021, Volume 14, 3197-3211.	0.8	2
193	Single-Cell Sequencing to Identify Six Heat Shock Protein (HSP) Genes-Mediated Progression Subtypes of Clear Cell Renal Cell Carcinoma. <i>International Journal of General Medicine</i> , 2021, Volume 14, 3761-3773.	0.8	3
194	Comprehensive Analysis of the Expression and Prognosis Value of Chromobox Family Members in Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 700528.	1.3	13
195	Development of a four-gene prognostic model for clear cell renal cell carcinoma based on transcriptome analysis. <i>Genomics</i> , 2021, 113, 1816-1827.	1.3	12
196	Development of a mechanically matched silk scaffolded 3D clear cell renal cell carcinoma model. <i>Materials Science and Engineering C</i> , 2021, 126, 112141.	3.8	8
197	ANGPTL3 Overexpression Suppresses the Development of Oncogenic Properties in Renal Cell Carcinoma via the Wnt/ $\beta$ -Catenin Signaling Pathway and Predicts Good Prognosis. <i>Disease Markers</i> , 2021, 2021, 1-8.	0.6	1
198	LncRNA GAS6 antisense RNA 1 facilitates the tumorigenesis of clear cell renal cell carcinoma by regulating the AMP-activated protein kinase/mTOR signaling pathway. <i>Oncology Letters</i> , 2021, 22, 727.	0.8	7
199	The levels of IL-6 and soluble IL-33R are increased in the renal vein during surgery for clear cell renal cell carcinoma. <i>Cytokine</i> , 2021, 144, 155586.	1.4	2
200	Multi-Omics Analysis of the Expression and Prognosis for FKBP Gene Family in Renal Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 697534.	1.3	10
201	Urine LOX-1 and Volatilome as Promising Tools towards the Early Detection of Renal Cancer. <i>Cancers</i> , 2021, 13, 4213.	1.7	15

#	ARTICLE	IF	CITATIONS
203	Antioxidant Gene Signature Impacts the Immune Infiltration and Predicts the Prognosis of Kidney Renal Clear Cell Carcinoma. <i>Frontiers in Genetics</i> , 2021, 12, 721252.	1.1	15
204	PD-1/PD-L1 inhibitors-based treatment for advanced renal cell carcinoma: Mechanisms affecting efficacy and combination therapies. <i>Cancer Medicine</i> , 2021, 10, 6384-6401.	1.3	10
205	Multidimensional Analyses of Tumor Immune Microenvironment Reveal the Possible Rationality of Immunotherapy and Identify High Immunotherapy Response Subtypes for Renal Papillary Cell Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 657951.	2.2	2
206	Prognostic significance and tumor-immune infiltration of mTOR in clear cell renal cell carcinoma. <i>PeerJ</i> , 2021, 9, e11901.	0.9	5
207	Bioinformatics analysis reveals biomarkers with cancer stem cell characteristics in kidney renal clear cell carcinoma. <i>Translational Andrology and Urology</i> , 2021, 10, 3501-3514.	0.6	0
208	Integrating HECW1 expression into the clinical indicators exhibits high accuracy in assessing the prognosis of patients with clear cell renal cell carcinoma. <i>BMC Cancer</i> , 2021, 21, 890.	1.1	7
210	A robust ferroptosis-related gene signature predicts overall survival in clear cell renal cell carcinoma. <i>Future Oncology</i> , 2021, 17, 4321-4341.	1.1	1
211	Comprehensive analysis of new prognostic signature based on ferroptosis-related genes in clear cell renal cell carcinoma. <i>Aging</i> , 2021, 13, 19789-19804.	1.4	9
212	PRR11 promotes ccRCC tumorigenesis by regulating E2F1 stability. <i>JCI Insight</i> , 2021, 6, .	2.3	6
213	TLR3 Serves as a Prognostic Biomarker and Associates with Immune Infiltration in the Renal Clear Cell Carcinoma Microenvironment. <i>Journal of Oncology</i> , 2021, 2021, 1-20.	0.6	9
214	Overexpression of IRF3 Predicts Poor Prognosis in Clear Cell Renal Cell Carcinoma. <i>International Journal of General Medicine</i> , 2021, Volume 14, 5675-5692.	0.8	10
215	Circular RNA EGLN3 silencing represses renal cell carcinoma progression through the miR-1224-3p/HMGXB3 axis. <i>Acta Histochemica</i> , 2021, 123, 151752.	0.9	10
216	Extracellular Vesicles and Cancer Stem Cells in Tumor Progression: New Therapeutic Perspectives. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10572.	1.8	12
217	Identification of a four-microRNA panel in serum for screening renal cell carcinoma. <i>Pathology Research and Practice</i> , 2021, 227, 153625.	1.0	10
218	USP39 promotes malignant proliferation and angiogenesis of renal cell carcinoma by inhibiting VEGF-A165b alternative splicing via regulating SRSF1 and SRPK1. <i>Cancer Cell International</i> , 2021, 21, 486.	1.8	15
219	The Clinical Relevance and Tumor Promoting Function of C19orf10 in Kidney Renal Clear Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 725959.	1.3	3
220	Quantitative evaluation of the dynamic activity of HeLa cells in different viability states using dynamic full-field optical coherence microscopy. <i>Biomedical Optics Express</i> , 2021, 12, 6431.	1.5	8
221	Checkpoint inhibitors in metastatic papillary renal cell carcinoma. <i>Cancer Treatment Reviews</i> , 2021, 99, 102228.	3.4	14

#	ARTICLE	IF	CITATIONS
222	Aberrant activation of m6A demethylase FTO renders HIF2 <sup>low</sup> clear cell renal cell carcinoma sensitive to BRD9 inhibitors. <i>Science Translational Medicine</i> , 2021, 13, eabf6045.	5.8	28
223	Role of Imaging in Renal Cell Carcinoma: A Multidisciplinary Perspective. <i>Radiographics</i> , 2021, 41, 1387-1407.	1.4	30
224	Germline mutation in the NBR1 gene involved in autophagy detected in a family with renal tumors. <i>Cancer Genetics</i> , 2021, 258-259, 51-56.	0.2	5
225	The role of immunotherapy in advanced renal cell carcinoma. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2021, 47, 1228-1242.	0.7	10
226	Downregulated METTL14 accumulates BPTF that reinforces super-enhancers and distal lung metastasis via glycolytic reprogramming in renal cell carcinoma. <i>Theranostics</i> , 2021, 11, 3676-3693.	4.6	69
227	Immunohistochemical expression of cd200 in renal cell carcinoma. <i>Journal of Microscopy and Ultrastructure</i> , 2021, 9, 136.	0.1	0
228	Pathology of Renal Cell Carcinoma. , 2020, , 49-72.		2
229	To be or not to be: whether anti-angiogenic agent combined with immune checkpoint inhibitor is necessary in the treatment of advanced or metastatic renal cell carcinoma. <i>Medical Oncology</i> , 2020, 37, 15.	1.2	5
230	Low intratumor heterogeneity correlates with increased response to PD-1 blockade in renal cell carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097711.	1.4	20
231	Basic Parameters of Blood Count, Serum Sodium, and Creatinine as Prognostic Factors for Renal Cell Carcinoma at Five-Year Follow-Up. <i>Medical Science Monitor</i> , 2018, 24, 3895-3902.	0.5	13
232	Modern approaches to kidney cancer immunotherapy. <i>Onkourologiya</i> , 2018, 14, 54-67.	0.1	15
233	Development and validation of a metastasis-associated prognostic signature based on single-cell RNA-seq in clear cell renal cell carcinoma. <i>Aging</i> , 2019, 11, 10183-10202.	1.4	28
234	Three-gene risk model in papillary renal cell carcinoma: a robust likelihood-based survival analysis. <i>Aging</i> , 2020, 12, 21854-21873.	1.4	19
235	Construction of circRNA-based ceRNA network to reveal the role of circRNAs in the progression and prognosis of metastatic clear cell renal cell carcinoma. <i>Aging</i> , 2020, 12, 24184-24207.	1.4	24
236	PTPRO predicts patient prognosis and correlates with immune infiltrates in human clear cell renal cell carcinoma. <i>Translational Cancer Research</i> , 2020, 9, 4800-4810.	0.4	10
237	An increased level of MiR-222-3p is associated with TMP2 suppression, ERK activation and is associated with metastasis and a poor prognosis in renal clear cell carcinoma. <i>Cancer Biomarkers</i> , 2020, 28, 141-149.	0.8	13
238	MicroRNA-222-3p promotes tumor cell migration and invasion and inhibits apoptosis, and is correlated with unfavorable prognosis of patients with renal cell carcinoma. <i>International Journal of Molecular Medicine</i> , 2019, 43, 525-534.	1.8	6
239	lncRNA small nucleolar RNA host gene 12 promotes renal cell carcinoma progression by modulating the miR-200c/collagen type I $\alpha 1$ chain pathway. <i>Molecular Medicine Reports</i> , 2020, 22, 3677-3686.	1.1	12

#	ARTICLE	IF	CITATIONS
240	Impact of inflammation and immunotherapy in renal cell carcinoma (Review). <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	19
241	Comprehensive pathway-related genes signature for prognosis and recurrence of ovarian cancer. <i>PeerJ</i> , 2020, 8, e10437.	0.9	1
242	ISPRF: a machine learning model to predict the immune subtype of kidney cancer samples by four genes. <i>Translational Andrology and Urology</i> , 2021, 10, 3773-3786.	0.6	6
243	Decreased interferon regulatory factor 6 expression due to DNA hypermethylation predicts an unfavorable prognosis in clear cell renal cell carcinoma. <i>Journal of Cancer</i> , 2021, 12, 6640-6655.	1.2	4
244	Doxycycline sensitizes renal cell carcinoma to chemotherapy by preferentially inhibiting mitochondrial translation. <i>Journal of International Medical Research</i> , 2021, 49, 030006052110443.	0.4	2
245	Single-Cell RNA Sequencing in Multiple Pathologic Types of Renal Cell Carcinoma Revealed Novel Potential Tumor-Specific Markers. <i>Frontiers in Oncology</i> , 2021, 11, 719564.	1.3	47
246	Genomic Instability Promotes the Progression of Clear Cell Renal Cell Carcinoma Through Influencing the Immune Microenvironment. <i>Frontiers in Genetics</i> , 2021, 12, 706661.	1.1	3
247	Kidney Carcinoma Ovarian Metastasis: Review of the Literature. <i>Cureus</i> , 2018, 10, e3620.	0.2	3
248	The role of protein arginine methyltransferases in kidney diseases. <i>Clinical Science</i> , 2020, 134, 2037-2051.	1.8	5
249	Overexpressing IFITM family genes predict poor prognosis in kidney renal clear cell carcinoma. <i>Translational Andrology and Urology</i> , 2021, 10, 3837-3851.	0.6	2
250	Rho guanine nucleotide exchange factor 39 increases the viability, migration and invasion of clear cell renal cell carcinoma cells via the activation of the AKT/ERK signaling pathway. <i>Genetics and Molecular Biology</i> , 2020, 43, e20190383.	0.6	1
251	The expression and prognostic value of RNA binding proteins in clear cell renal cell carcinoma. <i>Translational Cancer Research</i> , 2020, 9, 7415-7431.	0.4	5
252	Identification of a Prognostic Risk Signature of Kidney Renal Clear Cell Carcinoma Based on Regulating the Immune Response Pathway Exploration. <i>Journal of Oncology</i> , 2020, 2020, 1-8.	0.6	3
253	Development of Molecularly Targeted Agents in Early Phase Clinical Trials. , 2020, , 199-220.		0
254	GRIM19 deficiency promotes clear cell renal cell carcinoma progression and is associated with high TNM stage and Fuhrman grade. <i>Oncology Letters</i> , 2020, 19, 4115-4121.	0.8	2
255	EVALUATION OF THE EFFECTIVENESS OF MODERN IMMUNOTHERAPY. <i>Voprosy Onkologii</i> , 2020, 66, 211-217.	0.1	0
256	Establishment of a prognosis Prediction Model Based on Pyroptosis-Related Signatures Associated With the Immune Microenvironment and Molecular Heterogeneity in Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 755212.	1.3	21
257	Combination therapy with immune checkpoint inhibitors in advanced renal cell carcinoma: A meta-analysis of randomized controlled trials. <i>Clinical Immunology</i> , 2021, 232, 108876.	1.4	4

#	ARTICLE	IF	CITATIONS
258	Multifocal Renal Cell Carcinomas With Somatic IDH2 Mutation: Report of a Previously Undescribed Neoplasm. <i>American Journal of Surgical Pathology</i> , 2021, 45, 137-142.	2.1	5
259	Beyond Promoter: The Role of Macrophage in Invasion and Progression of Renal Cell Carcinoma. <i>Current Stem Cell Research and Therapy</i> , 2020, 15, 588-596.	0.6	4
260	Circ_0039569 promotes renal cell carcinoma growth and metastasis by regulating miR-34a-5p/CCL22. <i>American Journal of Translational Research (discontinued)</i> , 2019, 11, 4935-4945.	0.0	25
261	miR-625-3p promotes migration and invasion and reduces apoptosis of clear cell renal cell carcinoma. <i>American Journal of Translational Research (discontinued)</i> , 2019, 11, 6475-6486.	0.0	6
262	Next Generation Sequencing in Renal Cell Carcinoma: Towards Precision Medicine. <i>Kidney Cancer Journal: Official Journal of the Kidney Cancer Association</i> , 2019, 17, 94-104.	0.1	0
263	Tumor suppressor miR-33b-5p regulates cellular function and acts a prognostic biomarker in RCC. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 3346-3360.	0.0	4
264	USP22 promotes proliferation in renal cell carcinoma by stabilizing survivin. <i>Oncology Letters</i> , 2020, 20, 246.	0.8	0
265	Expression of CHL1 in Clear Cell Renal Cell Carcinoma and its Association With Prognosis. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2021, Publish Ahead of Print, 209-214.	0.6	2
266	Combination Therapy in Renal Cell Carcinoma: the Best Choice for Every Patient?. <i>Current Oncology Reports</i> , 2021, 23, 147.	1.8	15
267	Protein disulfide isomerase family 6 promotes the imatinib-resistance of renal cell carcinoma by regulation of Wnt3a-Frizzled1 axis. <i>Bioengineered</i> , 2021, 12, 12157-12166.	1.4	1
268	Methyltransferase-like 14 suppresses growth and metastasis of renal cell carcinoma by decreasing long noncoding RNA NEAT1. <i>Cancer Science</i> , 2022, 113, 446-458.	1.7	35
269	Integrative Analysis of Immune-Related Genes in the Tumor Microenvironment of Renal Clear Cell Carcinoma and Renal Papillary Cell Carcinoma. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 760031.	1.6	6
270	Identification of the Prognostic Value Among Suppressor Of Cytokine Signaling Family Members in Kidney Renal Clear Cell Carcinoma. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 585000.	1.6	1
271	Promising Therapeutic Targets in Kidney Renal Clear Cell Carcinoma: PLXNA1 and PLXNB3. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2021, , .	0.7	1
272	Ascorbic acid induced TET2 enzyme activation enhances cancer immunotherapy efficacy in renal cell carcinoma. <i>International Journal of Biological Sciences</i> , 2022, 18, 995-1007.	2.6	16
273	Establishment of a Prognostic Prediction and Drug Selection Model for Patients with Clear Cell Renal Cell Carcinoma by Multiomics Data Analysis. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-30.	1.9	6
274	Heterogeneity of tumor microenvironment is associated with clinical prognosis of non-clear cell renal cell carcinoma: a single-cell genomics study. <i>Cell Death and Disease</i> , 2022, 13, 50.	2.7	8
275	USP22 promotes proliferation in renal cell carcinoma by stabilizing survivin. <i>Oncology Letters</i> , 2020, 20, 1-1.	0.8	4



#	ARTICLE	IF	CITATIONS
276	KIF4A is a promising prognostic marker and correlates with immune infiltration in clear cell renal cell carcinoma. <i>Translational Cancer Research</i> , 2020, 9, 7165-7173.	0.4	2
277	A Novel Immune-Related ceRNA Network and Relative Potential Therapeutic Drug Prediction in ccRCC. <i>Frontiers in Genetics</i> , 2021, 12, 755706.	1.1	5
278	Improvement of Medical Treatment in Japanese Patients With Metastatic Renal Cell Carcinoma. <i>Cancer Diagnosis &amp; Prognosis</i> , 2022, 2, 25-30.	0.3	0
279	Identification and Verification of Tumor Immune Microenvironment-Related Prognostic Genes in Kidney Renal Clear Cell Carcinoma. <i>BioMed Research International</i> , 2022, 2022, 1-17.	0.9	5
280	A Novel Prognostic Signature for Survival Prediction and Immune Implication Based on SARS-CoV-2-Related Genes in Kidney Renal Clear Cell Carcinoma. <i>Frontiers in Bioengineering and Biotechnology</i> , 2021, 9, 744659.	2.0	8
281	Pyroptosis Regulators and Tumor Microenvironment Infiltration Characterization in Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 774279.	1.3	15
282	Adenovirus vaccine therapy with CD137L promotes CD8+ DCs-mediated multifunctional CD8+ T cell immunity and elicits potent anti-tumor activity. <i>Pharmacological Research</i> , 2022, 175, 106034.	3.1	6
283	The Impact of Modifying Sunitinib Treatment Scheduling on Renal Cancer Tumor Biology and Resistance. <i>Journal of Clinical Medicine</i> , 2022, 11, 369.	1.0	0
284	Reviewing Treatment Options for Advanced Renal Cell Carcinoma: Is There Still a Place for Tyrosine Kinase Inhibitor (TKI) Monotherapy?. <i>Advances in Therapy</i> , 2022, 39, 1107-1125.	1.3	10
285	Loss of CMTM6 promotes DNA damage-induced cellular senescence and antitumor immunity. <i>Oncot Immunology</i> , 2022, 11, 2011673.	2.1	21
286	Deubiquitylase OTUD6B stabilizes the mutated pVHL and suppresses cell migration in clear cell renal cell carcinoma. <i>Cell Death and Disease</i> , 2022, 13, 97.	2.7	11
287	PGK1 contributes to tumorigenesis and sorafenib resistance of renal clear cell carcinoma via activating CXCR4/ERK signaling pathway and accelerating glycolysis. <i>Cell Death and Disease</i> , 2022, 13, 118.	2.7	23
288	Circular RNAs and Drug Resistance in Genitourinary Cancers: A Literature Review. <i>Cancers</i> , 2022, 14, 866.	1.7	5
289	YAP1 activation promotes epithelial-mesenchymal transition and cell survival of renal cell carcinoma cells under shear stress. <i>Carcinogenesis</i> , 2022, 43, 301-310.	1.3	6
290	Cellular and Molecular Effects of Understudied Kinase Pregnancy Upregulated Non-Ubiquitous Calcium-Calmodulin Dependent Kinase (PNCK) in Renal Cell Carcinoma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
291	Claudin-10 overexpression suppresses human clear cell renal cell carcinoma growth and metastasis by regulating ATP5O and causing mitochondrial dysfunction. <i>International Journal of Biological Sciences</i> , 2022, 18, 2329-2344.	2.6	6
292	DLEU7-AS1 promotes renal cell cancer by silencing the miR-26a-5p/coronin-3 axis. <i>CKJ: Clinical Kidney Journal</i> , 0, , .	1.4	1
293	Cabozantinib plus Nivolumab: A Review in Advanced Renal Cell Carcinoma. <i>Targeted Oncology</i> , 2022, 17, 193-201.	1.7	2

#	ARTICLE	IF	CITATIONS
294	Rapamycin ameliorates chronic intermittent hypoxia and sleep deprivation-induced renal damage via the mammalian target of rapamycin (mTOR)/NOD-like receptor protein 3 (NLRP3) signaling pathway. <i>Bioengineered</i> , 2022, 13, 5537-5550.	1.4	4
295	Metastatic renal cell carcinoma in the maxilla: A case report. <i>Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology</i> , 2022, , .	0.2	0
296	LncRNA FAM13A-AS1 Promotes Renal Carcinoma Tumorigenesis Through Sponging miR-141-3p to Upregulate NEK6 Expression. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 738711.	1.6	7
297	A novel nine-microRNA-based model to improve prognosis prediction of renal cell carcinoma. <i>BMC Cancer</i> , 2022, 22, 264.	1.1	5
298	CCNA2 as an Immunological Biomarker Encompassing Tumor Microenvironment and Therapeutic Response in Multiple Cancer Types. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-35.	1.9	15
299	Identification of New m6A Methylation Modification Patterns and Tumor Microenvironment Infiltration Landscape that Predict Clinical Outcomes for Papillary Renal Cell Carcinoma Patients. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 818194.	1.8	1
300	Reshaping Treatment Paradigms for Advanced Renal Cell Cancer Patients and Improving Patient Management. <i>Current Treatment Options in Oncology</i> , 2022, 23, 609-629.	1.3	1
301	A novel role of TCAIM: suppressing renal carcinoma growth and enhancing its sensitivity to sunitinib. <i>FEBS Journal</i> , 2022, 289, 5259-5278.	2.2	0
302	Value of c-MET and Associated Signaling Elements for Predicting Outcomes and Targeted Therapy in Penile Cancer. <i>Cancers</i> , 2022, 14, 1683.	1.7	1
303	Downregulation of Circular RNA circPSD3 Promotes Metastasis by Modulating FBXW7 Expression in Clear Cell Renal Cell Carcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-18.	0.6	4
304	A Network Meta-Analysis of the Differences in Effectiveness and Safety between Nivolumab and Targeted Drug Therapy in Metastatic Renal Cell Carcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-8.	0.6	0
305	Identification of a Twelve Epithelial-Mesenchymal Transition-Related lncRNA Prognostic Signature in Kidney Clear Cell Carcinoma. <i>Disease Markers</i> , 2022, 2022, 1-18.	0.6	6
306	Recent Advances in Medical Therapy for Urological Cancers. <i>Frontiers in Oncology</i> , 2022, 12, 746922.	1.3	8
307	Construction and validation of a prognostic model for kidney renal clear cell carcinoma based on podocyte-associated genes. <i>Cancer Medicine</i> , 2022, , .	1.3	3
308	NF- $\kappa$ B and EGFR participate in S1PR3-mediated human renal cell carcinomas progression. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2022, 1868, 166401.	1.8	4
309	Identification of a Novel Defined Immune-Autophagy-Related Gene Signature Associated With Clinical and Prognostic Features of Kidney Renal Clear Cell Carcinoma. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 790804.	1.6	6
310	Systematic Pan-Cancer Analysis of KIF23 and a Prediction Model Based on KIF23 in Clear Cell Renal Cell Carcinoma (ccRCC). <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 1717-1729.	0.4	4
311	An immune-related lncRNA risk coefficient model to predict the outcomes in clear cell renal cell carcinoma. <i>Aging</i> , 2021, 13, 26046-26062.	1.4	7

#	ARTICLE	IF	CITATIONS
312	Wavelength Independent Photo-chemo Tri-Modal Combinatorial Renal Cell Carcinoma Therapy with Biocompatible Gold-Titanium Nanostars. <i>Advanced Therapeutics</i> , 2022, 5, 2100204.	1.6	0
313	Renal Cell Carcinoma: Case Report and Aeromedical Consideration. <i>Hang'gong Uju Uihaghoeji</i> , 2021, 31, 84-85.	0.2	1
314	SIRT5 functions as a tumor suppressor in renal cell carcinoma by reversing the Warburg effect. <i>Journal of Translational Medicine</i> , 2021, 19, 521.	1.8	20
315	Assessment of the prognostic value of SPOCK1 in clear cell renal cell carcinoma: a bioinformatics analysis. <i>Translational Andrology and Urology</i> , 2022, 11, 509-518.	0.6	4
316	Identification of BAP1 mutation as a common mutation correlated with tumor mutation burden and immune infiltration in kidney renal clear cell carcinoma. <i>International Journal of Transgender Health</i> , 2022, 15, 470-478.	1.1	3
317	Novel immune-related signature based on immune cells for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma. <i>Journal of Clinical Laboratory Analysis</i> , 2022, , e24409.	0.9	1
336	OIP5 Is a Novel Prognostic Biomarker in Clear Cell Renal Cell Cancer Correlating With Immune Infiltrates. <i>Frontiers in Immunology</i> , 2022, 13, 805552.	2.2	7
337	Renal cell carcinoma-derived exosomes deliver IncARSR to induce macrophage polarization and promote tumor progression via STAT3 pathway. <i>International Journal of Biological Sciences</i> , 2022, 18, 3209-3222.	2.6	37
338	Ball-shaped right atrial mass in renal cell carcinoma: A case report. <i>World Journal of Critical Care Medicine</i> , 2022, 11, 192-197.	0.8	0
339	Molecular Imaging of Renal Cell Carcinoma in Precision Medicine. <i>Molecular Pharmaceutics</i> , 2022, 19, 3457-3470.	2.3	5
340	Circular RNA circVAMP3 promotes aerobic glycolysis and proliferation by regulating LDHA in renal cell carcinoma. <i>Cell Death and Disease</i> , 2022, 13, 443.	2.7	7
341	Integration of Tumor Microenvironment in Patient-Derived Organoid Models Help Define Precision Medicine of Renal Cell Carcinoma. <i>Frontiers in Immunology</i> , 2022, 13, 902060.	2.2	3
342	Comprehensive Genomic Characterization of Tumor Microenvironment and Relevant Signature in Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	0
343	Black Phosphorus Quantum Dots Enhance the Radiosensitivity of Human Renal Cell Carcinoma Cells through Inhibition of DNA-PKcs Kinase. <i>Cells</i> , 2022, 11, 1651.	1.8	3
344	Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial. <i>Clinical Cancer Research</i> , 2022, 28, 3248-3255.	3.2	24
345	Therapeutic Potential of Natural Products in the Treatment of Renal Cell Carcinoma: A Review. <i>Nutrients</i> , 2022, 14, 2274.	1.7	3
346	Blockade LAT1 Mediates Methionine Metabolism to Overcome Oxaliplatin Resistance under Hypoxia in Renal Cell Carcinoma. <i>Cancers</i> , 2022, 14, 2551.	1.7	2
347	The Ion Channel-Related Gene Signatures Correlated With Diagnosis, Prognosis, and Individualized Treatment in Patients With Clear Cell Renal Cell Carcinoma. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	6

#	ARTICLE	IF	CITATIONS
348	Identification and Verification of Immune Subtype-Related lncRNAs in Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
350	IFI35 Promotes Renal Cancer Progression by Inhibiting pSTAT1/pSTAT6-Dependent Autophagy. <i>Cancers</i> , 2022, 14, 2861.	1.7	4
351	A promising Prognostic risk model for advanced renal cell carcinoma (RCC) with immune-related genes. <i>BMC Cancer</i> , 2022, 22, .	1.1	9
352	ARL4C Regulates the Progression of Clear Cell Renal Cell Carcinoma by Affecting the Wnt/ $\beta$ 2-Catenin Signaling Pathway. <i>Journal of Oncology</i> , 2022, 2022, 1-24.	0.6	4
353	Immune checkpoint inhibitor-based therapy for advanced clear cell renal cell carcinoma: A narrative review. <i>International Immunopharmacology</i> , 2022, 110, 108900.	1.7	13
354	The Transcriptional and Immunological Roles of Six2 in Clear Cell Renal Cell Carcinoma. <i>Oncologie</i> , 2022, 24, 261-282.	0.2	2
355	Macrophage Phenotype in Combination with Tumor Microbiome Composition Predicts RCC Patients' Survival: A Pilot Study. <i>Biomedicines</i> , 2022, 10, 1516.	1.4	4
356	External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database. <i>Clinical Genitourinary Cancer</i> , 2023, 21, 175-182.	0.9	2
357	A Predictive Model Based on Pyroptosis-Related Gene Features Can Effectively Predict Clear Cell Renal Cell Carcinoma Prognosis and May Be an Underlying Target for Immunotherapy. <i>Disease Markers</i> , 2022, 2022, 1-21.	0.6	0
358	A Fatty Acid Metabolism Signature Associated With Clinical Therapy in Clear Cell Renal Cell Carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	5
359	Myocardial Ischemia Related to Common Cancer Therapy's Prevention Insights. <i>Life</i> , 2022, 12, 1034.	1.1	1
360	Aurora-A/FOXO3A/SKP2 axis promotes tumor progression in clear cell renal cell carcinoma and dual-targeting Aurora-A/SKP2 shows synthetic lethality. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	9
361	Single-cell multiomics analysis reveals regulatory programs in clear cell renal cell carcinoma. <i>Cell Discovery</i> , 2022, 8, .	3.1	32
362	Knowledge mapping and research hotspots of immunotherapy in renal cell carcinoma: A text-mining study from 2002 to 2021. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	15
363	Interleukin 20 receptor subunit beta (IL20RB) predicts poor prognosis and regulates immune cell infiltration in clear cell renal cell carcinoma. <i>BMC Genomic Data</i> , 2022, 23, .	0.7	3
364	Combination of sunitinib and 177Lu-labeled antibody cG250 targeted radioimmunotherapy: A promising new therapeutic strategy for patients with advanced renal cell cancer. <i>Neoplasia</i> , 2022, 32, 100826.	2.3	0
365	Clinical Efficacy of PD-1 Inhibitors Plus Split-Course Radiotherapy in the First-Line Treatment of Advanced Kidney Cancer: A Randomized Controlled Trial. <i>Journal of Oncology</i> , 2022, 2022, 1-6.	0.6	1
366	Identification of ferroptosis-related signature with potential implications in prognosis and immunotherapy of renal cell carcinoma. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2022, 27, 946-960.	2.2	2

#	ARTICLE	IF	CITATIONS
367	Perirenal Fat Thickness Significantly Associated with Prognosis of Metastatic Renal Cell Cancer Patients Receiving Anti-VEGF Therapy. <i>Nutrients</i> , 2022, 14, 3388.	1.7	1
368	Clinical outcomes of robotic-assisted laparoscopic partial nephrectomy with renal hypothermia perfusion by renal artery balloon catheter in treating patients with complex renal tumors. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
369	Interleukin 17 and Its Involvement in Renal Cell Carcinoma. <i>Journal of Clinical Medicine</i> , 2022, 11, 4973.	1.0	3
370	FBP1 /miR-24-1/enhancer axis activation blocks renal cell carcinoma progression via Warburg effect. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
371	Dysregulation and implications of N6-methyladenosine modification in renal cell carcinoma. <i>Current Urology</i> , 2023, 17, 45-51.	0.4	1
372	Successful Surgical Management of Locally Advanced Renal Cell Carcinoma Invading Spleen and Pancreas. <i>Journal of Kidney Cancer and VHL</i> , 2022, 9, 1-4.	0.2	0
373	LncRNA MILIP links YBX1 to translational activation of Snai1 and promotes metastasis in clear cell renal cell carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, .	3.5	16
375	The tumorâ€repressing effect of <sc>CYP27A1</sc> on renal cell carcinoma by <sc>27â€HC</sc> arising from cholesterol metabolism. <i>FASEB Journal</i> , 2022, 36, .	0.2	1
376	Integrated multi-omics analyses reveal that BCAM is associated with epigenetic modification and tumor microenvironment subtypes of clear cell renal cell carcinoma. <i>Clinical Epigenetics</i> , 2022, 14, .	1.8	1
377	Selenium substituted axitinib reduces axitinib side effects and maintains its anti-renal tumor activity. <i>RSC Advances</i> , 2022, 12, 21821-21826.	1.7	3
378	Correlation between Genes of the ceRNA Network and Tumor-Infiltrating Immune Cells and Their Biomarker Screening in Kidney Renal Clear Cell Carcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-15.	0.6	1
379	Identification of EZH2 as Cancer Stem Cell Marker in Clear Cell Renal Cell Carcinoma and the Anti-Tumor Effect of Epigallocatechin-3-Gallate (EGCG). <i>Cancers</i> , 2022, 14, 4200.	1.7	9
380	C chemokines are prognostic biomarkers correlated with diverse immune cell infiltrations in clear cell renal cell carcinoma. <i>Translational Cancer Research</i> , 2022, 11, 2501-2522.	0.4	2
381	Emerging role of extracellular vesicles in kidney diseases. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
382	Combining expression of <sc>RNF43</sc> and infiltration level of <sc>CD163</sc> <sup>+</sup> tumor associated macrophage predicts prognosis of clear cell renal cell carcinoma. <i>Cancer Medicine</i> , 0, , .	1.3	2
383	Identification of key somatic oncogenic mutation based on a confounder-free causal inference model. <i>PLoS Computational Biology</i> , 2022, 18, e1010529.	1.5	1
384	Nomograms for predicting overall and cancer-specific survival of patients with chromophobe renal cell carcinoma after nephrectomy: a retrospective SEER-based study. <i>BMJ Open</i> , 2022, 12, e062129.	0.8	0
385	<sc>AKG</sc> induces cell apoptosis by inducing reactive oxygen speciesâ€mediated endoplasmic reticulum stress and by suppressing <sc>PI3K</sc>/<sc>AKT</sc>/<sc>mTOR</sc>â€mediated autophagy in renal cell carcinoma. <i>Environmental Toxicology</i> , 2023, 38, 17-27.	2.1	2

#	ARTICLE	IF	CITATIONS
386	Radical cystectomy for bladder urothelial carcinoma with aggressive variant histology. <i>Archivio Italiano Di Urologia Andrologia</i> , 2022, 94, 291-294.	0.4	2
387	Prognostic, Clinicopathological, and Function of Key Cuproptosis Regulator FDX1 in Clear Cell Renal Cell Carcinoma. <i>Genes</i> , 2022, 13, 1725.	1.0	2
388	A new CCCH-type zinc finger-related lncRNA signature predicts the prognosis of clear cell renal cell carcinoma patients. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
389	A Novel Cuproptosis-Related Gene FDX1 Signature for Overall Survival Prediction in Clear Cell Renal Cell Carcinoma Patients. <i>BioMed Research International</i> , 2022, 2022, 1-16.	0.9	8
390	Identification of novel mycocompounds as inhibitors of PI3K/AKT/mTOR pathway against RCC. <i>Journal of Receptor and Signal Transduction Research</i> , 2022, 42, 599-607.	1.3	1
391	Molecular mechanisms of resistance to tyrosine kinase inhibitor in clear cell renal cell carcinoma. <i>International Journal of Urology</i> , 2022, 29, 1419-1428.	0.5	4
392	A newly defined basement membrane-related gene signature for the prognosis of clear-cell renal cell carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	6
393	MND1 functions as a potential prognostic biomarker associated with cell cycle and immune infiltration in kidney renal clear cell carcinoma. <i>Aging</i> , 2022, 14, 7416-7442.	1.4	3
394	HIF1A predicts the efficacy of anti-PD-1 therapy in advanced clear cell renal cell carcinoma. <i>Translational Oncology</i> , 2022, 26, 101554.	1.7	2
395	RNF43 is a novel tumor-suppressor and prognostic indicator in clear cell renal cell carcinoma. <i>Oncology Research</i> , 2021, 29, 159-174.	0.6	1
396	LncRNA FEZF1-AS1 negatively regulates ETNK1 to promote malignant progression of renal cell carcinoma. <i>Journal of Medical Biochemistry</i> , 0, , .	0.7	0
397	Extracellular Vesicle-Mediated Transfer of LncRNA <i>IGFL2-AS1</i> Confers Sunitinib Resistance in Renal Cell Carcinoma. <i>Cancer Research</i> , 2023, 83, 103-116.	0.4	17
398	Downregulation of FXRD2 Is Associated with Poor Prognosis and Increased Regulatory T Cell Infiltration in Clear Cell Renal Cell Carcinoma. <i>Journal of Immunology Research</i> , 2022, 2022, 1-19.	0.9	1
399	A comprehensive investigation discovered the novel methyltransferase METTL24 as one presumably prognostic gene for kidney renal clear cell carcinoma potentially modulating tumor immune microenvironment. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
400	miR-378a-3p promotes renal cell carcinoma proliferation, migration, and invasion by targeting TOB2. <i>Clinical and Translational Oncology</i> , 2023, 25, 748-757.	1.2	1
401	Expression of basement membrane genes and their prognostic significance in clear cell renal cell carcinoma patients. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
402	Alpha $\alpha$ 2 $\mu$ Heremans $\alpha$ Schmid $\alpha$ glycoprotein (AHSG) a potential biomarker associated with prognosis of chromophobe renal cell carcinoma: The PROPOLIS study. <i>Health Science Reports</i> , 2022, 5, .	0.6	1
403	Comprehensive exploration of the expression and prognostic value of AQP <sub>s</sub> in clear cell renal cell carcinoma. <i>Medicine (United States)</i> , 2022, 101, e29344.	0.4	4

#	ARTICLE	IF	CITATIONS
404	Development of genomic instability-associated long non-coding RNA signature: A prognostic risk model of clear cell renal cell carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
405	Imidazolylpyrrolone-based small molecules as anticancer agents for renal cell carcinoma. <i>ChemMedChem</i> , 0, , .	1.6	1
406	High expression of TTC21A predicts unfavorable prognosis and immune infiltrates in clear cell renal cell carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
407	Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: A three-arm, randomised, double-blind, multicentre phase III study (CONCEPT). <i>European Journal of Cancer</i> , 2023, 178, 205-215.	1.3	4
408	Lysosomal-Associated Transmembrane Protein 5 Promotes Proliferation, Migration, and Invasion of Clear Cell Renal Cell Carcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-18.	0.6	0
409	Smart Milli-capsules manipulated by nIR irradiation for controllable drug delivery in-vivo for renal cell carcinoma and neurodegenerative diseases. <i>Materials and Design</i> , 2022, 224, 111287.	3.3	2
410	Macrophage-Specific Cathepsin as a Marker Correlated with Prognosis and Tumor Microenvironmental Characteristics of Clear Cell Renal Cell Carcinoma. <i>Journal of Inflammation Research</i> , 0, Volume 15, 6275-6292.	1.6	1
411	Cellular and molecular effects of PNCK, a non-canonical kinase target in renal cell carcinoma. <i>IScience</i> , 2022, 25, 105621.	1.9	2
412	Identifying Prognostic Biomarkers Related to m6A Modification and Immune Infiltration in Renal Cell Carcinoma. <i>Genes</i> , 2022, 13, 2059.	1.0	2
413	CircSCNN1A is a tumor suppressor in renal cell carcinoma via inducing the upregulation of MPP7 by the sponge effect on miR-421. <i>Transplant Immunology</i> , 2022, 75, 101736.	0.6	1
414	Exosomes in Genitourinary Cancers: Emerging Mediators of Drug Resistance and Promising Biomarkers. <i>International Journal of Biological Sciences</i> , 2023, 19, 167-182.	2.6	3
415	Therapeutic sequencing in advanced renal cell carcinoma: How to choose considering clinical and biological factors. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 181, 103881.	2.0	3
416	Patient-derived organoids potentiate precision medicine in advanced clear cell renal cell carcinoma. <i>Precision Clinical Medicine</i> , 2022, 5, .	1.3	3
417	CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	24
418	Clinical significance and immune landscape of cuproptosis-related lncRNAs in kidney renal clear cell carcinoma: a bioinformatical analysis. <i>Annals of Translational Medicine</i> , 2022, 10, 1235-1235.	0.7	5
419	Real-World Study Evaluating Safety and Effectiveness of Axitinib in Korean Patients with Renal Cell Carcinoma after Failure of One Prior Systemic Therapy. <i>Cancer Research and Treatment</i> , 2023, 55, 643-651.	1.3	1
420	Impact of low and high body mass index on predicting therapeutic efficacy and prognosis in patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors. <i>International Journal of Urology</i> , 0, , .	0.5	1
421	Epstein-Barr Virus (EBV) Epithelial Associated Malignancies: Exploring Pathologies and Current Treatments. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14389.	1.8	11

#	ARTICLE	IF	CITATIONS
422	Role of tumor-derived exosomes in metastasis, drug resistance and diagnosis of clear cell renal cell carcinoma. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
424	A Novel Cuproptosis-Related Prognostic Model and the Hub Gene FDX1 Predict the Prognosis and Correlate with Immune Infiltration in Clear Cell Renal Cell Carcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-19.	0.6	1
425	A novel biflavone from <i>Reineckia carnea</i> induces apoptosis of human renal cancer 786-O cells. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
426	Cuproptosis-Related Genes Are Associated with Cell Cycle and Serve as the Prognostic Signature for Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Medicine</i> , 2022, 11, 7507.	1.0	0
427	NUDT1 Could Be a Prognostic Biomarker and Correlated with Immune Infiltration in Clear Cell Renal Cell Carcinoma. <i>Applied Bionics and Biomechanics</i> , 2022, 2022, 1-16.	0.5	2
428	circPLIN2 promotes clear cell renal cell carcinoma progression by binding IGF2BP proteins and miR-199a-3p. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	5
429	Hybrid Metabolic Activity-Related Prognostic Model and Its Effect on Tumor in Renal Cell Carcinoma. <i>Journal of Healthcare Engineering</i> , 2022, 2022, 1-17.	1.1	0
430	Cardiotoxicity of Selected Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Renal Cell Carcinoma. <i>Biomedicines</i> , 2023, 11, 181.	1.4	4
432	Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers. <i>Drug Resistance Updates</i> , 2023, 67, 100929.	6.5	23
433	Nanomedicine for renal cell carcinoma: imaging, treatment and beyond. <i>Journal of Nanobiotechnology</i> , 2023, 21, .	4.2	4
434	Single-cell RNA-seq integrated with multi-omics reveals SERPINE2 as a target for metastasis in advanced renal cell carcinoma. <i>Cell Death and Disease</i> , 2023, 14, .	2.7	8
435	Does red blood cell distribution width predict prognosis in metastatic renal cell carcinoma patients using first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy?. <i>Journal of Cancer Research and Therapeutics</i> , 2023, .	0.3	2
436	CircCCDC66: Emerging roles and potential clinical values in malignant tumors. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
437	Identification and Validation of the Prognostic Panel in Clear Cell Renal Cell Carcinoma Based on Resting Mast Cells for Prediction of Distant Metastasis and Immunotherapy Response. <i>Cells</i> , 2023, 12, 180.	1.8	2
438	Higher TYROBP and lower SOX6 as predictive biomarkers for poor prognosis of clear cell renal cell carcinoma: A pilot study. <i>Medicine (United States)</i> , 2022, 101, e30658.	0.4	1
440	The LncRNA signature associated with cuproptosis as a novel biomarker of prognosis in immunotherapy and drug screening for clear cell renal cell carcinoma. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	0
441	Pyroptosis in urinary malignancies: a literature review. <i>Discover Oncology</i> , 2023, 14, .	0.8	1
442	Everolimus and tamsirolimus are not the same second-line in metastatic renal cell carcinoma: a systematic review and meta-analysis. <i>Cost Effectiveness and Resource Allocation</i> , 2023, 21, .	0.6	1



#	ARTICLE	IF	CITATIONS
443	Integrated analysis of the relation to tumor immune microenvironment and predicted value of Stonin1 gene for immune checkpoint blockage and targeted treatment in kidney renal clear cell carcinoma. BMC Cancer, 2023, 23, .	1.1	0
444	Î²â€one represses renal cell carcinoma progression through activating LKB1/AMPKâ€triggered autophagy. Journal of Biochemical and Molecular Toxicology, 2023, 37, .	1.4	1
445	Cellâ€cell communications shape tumor microenvironment and predict clinical outcomes in clear cell renal carcinoma. Journal of Translational Medicine, 2023, 21, .	1.8	2
447	ZNF582 overexpression restrains the progression of clear cell renal cell carcinoma by enhancing the binding of TJP2 and ERK2 and inhibiting ERK2 phosphorylation. Cell Death and Disease, 2023, 14, .	2.7	2
448	Incidence, Prognostic Factors, and Survival of Patients with Renal Cancer: A Population-Based Study. Journal of Investigative Surgery, 2023, 36, .	0.6	2
449	Comprehensive analysis of prognostic value, immune implication and biological function of CPNE1 in clear cell renal cell carcinoma. Frontiers in Cell and Developmental Biology, 0, 11, .	1.8	1
450	Metastasis in renal cell carcinoma: Biology and treatment. Advances in Cancer Biology Metastasis, 2023, 7, 100094.	1.1	0
451	ORP8 inhibits renal cell carcinoma progression by accelerating Stathmin1 degradation and microtubule polymerization. Experimental Cell Research, 2023, 427, 113601.	1.2	0
452	Adjuvant Therapy for Renal Cell Carcinoma: End Points, Outcomes, and Risk Assessments. JCO Precision Oncology, 2023, , .	1.5	1
453	The Effects of circ_000558/miR-1225-5p/ARL4C on Regulating the Proliferation of Renal Cell Carcinoma Cells. Journal of Oncology, 2023, 2023, 1-12.	0.6	1
454	The role of spatial interplay patterns between PD-L1-positive tumor cell and T cell in recurrence of locally advanced non-small cell lung cancer. Cancer Immunology, Immunotherapy, 2023, 72, 2015-2027.	2.0	1
455	Identification of Immune-Related Seven-Long Non-Coding RNA Signature for Overall Survival and Validation of the Effect of LINC01270 in Malignant Phenotypes of Clear Cell Renal Carcinoma. Cancer Management and Research, 0, Volume 15, 131-145.	0.9	0
456	SLC9A1 Binding mTOR Signaling Pathway-Derived Risk Score Predicting Survival and Immune in Clear Cell Renal Cell Carcinoma. Journal of Oncology, 2023, 2023, 1-14.	0.6	0
457	Development and validation of a nomogram to evaluate the therapeutic effects of second-line axitinib in patients with metastatic renal cell carcinoma. Frontiers in Oncology, 0, 13, .	1.3	0
458	Comparing efficacy and safety of first-line treatment of metastatic renal cell carcinoma: A Bayesian network meta-regression analysis. Frontiers in Oncology, 0, 13, .	1.3	0
459	Clear Cell Renal Cell Carcinoma: A Comprehensive in silico Study in Searching for Therapeutic Targets. Kidney and Blood Pressure Research, 2023, 48, 135-150.	0.9	2
460	FAK-mediated phosphorylation at Y464 regulates p85Î² nuclear translocation to promote tumorigenesis of ccRCC by repressing RB1 expression. Cell Reports, 2023, 42, 112188.	2.9	1
461	N6â€methyladenosineâ€modified <i>DBT</i> alleviates lipid accumulation and inhibits tumor progression in clear cell renal cell carcinoma through the ANXA2/YAP axisâ€regulated Hippo pathway. Cancer Communications, 2023, 43, 480-502.	3.7	11

#	ARTICLE	IF	CITATIONS
462	miR-613 suppresses renal cell carcinoma proliferation, invasion and migration by regulating the AXL/AKT pathway. <i>Experimental Biology and Medicine</i> , 2023, 248, 281-292.	1.1	0
463	Endoplasmic Reticulum Stress in Renal Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4914.	1.8	3
464	The New Frontier of Immunotherapy: Chimeric Antigen Receptor T (CAR-T) Cell and Macrophage (CAR-M) Therapy against Breast Cancer. <i>Cancers</i> , 2023, 15, 1597.	1.7	6
465	Establishment of a new prognostic risk model of MAPK pathway-related molecules in kidney renal clear cell carcinoma based on genomes and transcriptomes analysis. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
466	High GTSE1 expression promotes cell proliferation, metastasis and cisplatin resistance in ccRCC and is associated with immune infiltrates and poor prognosis. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	0
467	Optimal sequential therapy using tyrosine kinase inhibitors as the 1st-line treatment in patients with metastatic renal cell carcinoma: A nationwide multicenter study. <i>Asian Journal of Urology</i> , 2023, , .	0.5	0
468	Integrated bioinformatic analysis and cell line experiments reveal the significant role of the novel immune checkpoint TIGIT in kidney renal clear cell carcinoma. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
469	Using machine learning to predict lymph node metastasis in patients with renal cell carcinoma: A population-based study. <i>Frontiers in Public Health</i> , 0, 11, .	1.3	3
470	LZTFL1 inhibits kidney tumor cell growth by destabilizing AKT through ZNRF1-mediated ubiquitin proteasome pathway. <i>Oncogene</i> , 0, , .	2.6	0
471	Immunogenicity in renal cell carcinoma: shifting focus to alternative sources of tumour-specific antigens. <i>Nature Reviews Nephrology</i> , 2023, 19, 440-450.	4.1	4
472	The m6A-regulation and single cell effect pattern in sunitinib resistance on clear cell renal cell carcinoma: Identification and validation of targets. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	0
473	<sc>KLF9</sc> inhibits the proliferation, invasion, and migration of renal cell carcinoma through the <sc>SDF</sc>â€1</sc><sc>CXCR4</sc> axis. <i>Kaohsiung Journal of Medical Sciences</i> , 2023, 39, 587-595.	0.8	2
474	A 20-Gene Signature Predicting Survival in Patients with Clear Cell Renal Cell Carcinoma Based on Basement Membrane. <i>Journal of Oncology</i> , 2023, 2023, 1-11.	0.6	0
475	Re: Matthew S. Ernst, Vishal Navani, J. Connor Wells, et al. Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma. <i>Eur Urol</i> . In press. <a href="https://doi.org/10.1016/j.eururo.2023.01.001">https://doi.org/10.1016/j.eururo.2023.01.001</a> . <i>European Urology</i> , 2023, , .	0.9	0
478	Low Expression of TSTD2 Serves as a Biomarker for Poor Prognosis in Kidney Renal Clear Cell Carcinoma. <i>International Journal of General Medicine</i> , 0, Volume 16, 1437-1453.	0.8	0
539	Adjuvant Treatment and Follow-Up of Clinically Localized Renal Cell Carcinoma. , 2023, , 53-70.		0
544	Molecular insight into renal cancer and latest therapeutic approaches to tackle it: anÂupdatedÂreview. , 2023, 40, .		0
554	Fucoidan sulfate from <i>Sargassum fusiforme</i> regulates the SARS-CoV-2 receptor AXL expression in human embryonic lung diploid fibroblast cells. <i>Journal of Zhejiang University: Science B</i> , 2023, 24, 1047-1052.	1.3	0

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------